As you may know, I like to follow along as new IBS drugs make their way along the pipeline. I had my eye on one called MuDelta, designed for the treatment of of IBS-D:
The medication has now been named "eluxadoline" and has recently completed a Phase II clinical trial. According to the study abstract, approximately 800 patients were randomly assigned to recieve either a placebo or various dosage levels of the medication for a period of 12 weeks. With results varying depending on dosage level, in general, those given the medication were more likely to experience improvement in terms of "abdominal pain and stool consistency". As for side effects, the abstract reports that the medication was "well tolerated with a low incidence of constipation".
The medication still has to make its way through the rest of the clinical trial process, but this is encouraging news, as goodness knows the medication options for IBS-D are extremely limited.
Related Reading from Dr. Bolen, Your IBS Guide:
Dove, L., et.al. "Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study" Gastroenterology 2013 145:329-338.
|My Bio | Facebook | Twitter | Google+ | Newsletter Signup|